NCT00158743 - Efficacy Study of Digibind for Treatment of Severe Preeclampsia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Pre-eclampsia

Interventions

DRUG

Anti-digoxin antibody (FAB fragment)

intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.

OTHER

sodium chloride

Trial Locations (8)

Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 634, PO Box 250619, Charleston

Winnie Palmer Hospital, Orlando

University of South Alabama, Mobile

St Mary's Health Center, St Louis

Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, PO Box 33932, 1501 Kings Highway, Shreveport

St Mark's Hospital, Salt Lake City

Phoenix Perinatal Associates, Phoenix

Department of OB-GYN, Division of Maternal Fetal Medicine, University of Texas Medical Branch, 301 University Boulevard, Galveston